Vmbook Online ordering

Coherent Inc

COHR (trading as Coherus Biosciences, Inc.) is a public company that specializes in the development and commercialization of biosimilar therapeutics. A biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from, an existing FDA-approved reference product.

When it comes to key financials, here is some general information as of the time of writing:

* Market Capitalization: ~ $1.7 billion

* Trailing 12-month Revenue: $153 million

* Earnings (ttm): -$126 million

* Price-to-Sales (ttm): 11.3x

Please note that financial figures are approximate and are subject to change. It is always best to verify financial data by checking a reliable source such as a financial news site or the company's official investor relations website.

Regarding growth, Coherus Biosciences has experienced significant revenue growth in recent years. In 2019, the company reported revenues of $54 million, up from $12 million in 2018. However, it's important to note that the company has experienced net losses in recent years.

In terms of its product portfolio, Coherus Biosciences has several biosimilar candidates in its pipeline, including CHS-1420, a biosimilar candidate referencing Humira (adalimumab), which has been approved by the FDA for various indications.

It is important to conduct your own research or consult a financial advisor when making investment decisions, as the information provided here does not constitute financial advice. Furthermore, this information is accurate as of the time of writing and is subject to change.